

**Table 1: Demographics, clinical features, medications, autoantibodies at enrolment.**

Number of Patients		1826
Sex (%)	Female	1622 (88.8)
	Male	204 (11.2)
Age (years) (mean $\pm$ SD)		35.1 $\pm$ 13.3
Race/Ethnicity (%)	Caucasian	891 (48.8)
	African	306 (16.8)
	Hispanic	282 (15.4)
	Asian	275 (15.1)
	Other	72 (3.9)
Single/Married/Other (%)		818 (44.9)/766 (42.0)/238 (13.1)
Post-secondary education (%)		1064 (61.9)
Disease duration (months) (mean $\pm$ SD)		5.6 $\pm$ 4.2
Number of ACR criteria (mean $\pm$ SD)		4.9 $\pm$ 1.1
ACR manifestations (%)	Malar rash	660 (36.1)
	Discoid rash	227 (12.4)
	Photosensitivity	652 (35.7)
	Oral/nasal ulcers	677 (37.1)
	Serositis	502 (27.5)
	Arthritis	1368 (74.9)
	Renal disorder	510 (27.9)
	Neurological disorder	88 (4.8)
	Hematologic disorder	1129 (61.8)
	Immunologic disorder	1392 (76.2)
	Antinuclear antibody	1731 (94.8)
SLEDAI-2K score (mean $\pm$ SD)		5.3 $\pm$ 5.4
*SLICC/ACR damage index score (mean $\pm$ SD)		0.32 $\pm$ 0.74
Medications (%)	Corticosteroids	1284 (70.3)
	Antimalarials	1231 (67.4)
	Immunosuppressants	732 (40.1)
	ASA	261 (14.3)
	Antidepressants	183 (10.0)

	Warfarin	99 (5.4)
	Anticonvulsants	80 (4.4)
	Antipsychotics	12 (0.7)
Autoantibody positivity N (%)	Lupus anticoagulant	241/1174 (20.5)
	Anti-cardiolipin	138/1142 (12.1)
	Anti-Beta2 glycoprotein-I	163/1142 (14.3)
	Anti-ribosomal P	112/1136 (9.9)
	Anti-NR2	130/1064 (12.2)

\*SLICC/ACR damage index not available in 1057 patients at enrollment visit when disease duration < 6 months